Skip to content

Allison A. Feduccia

22 papers in the library · 2,505 citations · publishing 2008-2026

Papers

Sort Most recent Most cited

Patterns of Psychedelic Use in Italy: Insights from the Global Psychedelic Survey

Clinical Neuropsychopharmacology and Addiction September 1, 2026 Beatrice Dal Bianco, Matteo Buonarroti, Alessandro Lo Jacono et al.

Background: Epidemiological data on psychedelic use in Italy is limited. In this study, Italian responders in the Global Psychedelic Survey 2025 were subanalyzed to describe patterns of use, motivations, subjective experiences, and health correlates. Methods: Adults (≥21 years) with lifetime psychedelic exposure, residing in or born in Italy or San Marino, were surveyed in a web-based,...

Development of the MDMA-Assisted Psychotherapy Side Effects Tool (M-SET): a Delphi study.

BMJ Open May 11, 2026 Julia Colcott, Alexandre A. Guerin, Olivia Carter et al.

Despite growing interest in the therapeutic potential of 3,4-methylenedioxymethamphetamine (MDMA), no targeted measure to systematically assess side effects of MDMA-assisted psychotherapy (MDMA-AP) exists. Our aim was to develop an MDMA-Assisted Psychotherapy Side Effects Tool (M-SET) to capture side effects over the course of MDMA-AP. Informed by a systematic review and a review of other...

The need for establishing best practices and gold standards in psychedelic medicine.

Journal of Affective Disorders July 1, 2023 Allison A. Feduccia, Gabby Agin-Liebes, Collin M. Price et al. 38 citations

Psychedelic substances are under investigation in several drug development programs. Controlled clinical trials are providing evidence for safe and effective use of psychedelic therapies for treating mental health conditions. With the anticipated FDA approval of MDMA-assisted therapy for posttraumatic stress disorder in 2023 and psilocybin therapy for depression disorders soon after, now is the...

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline.

FOCUS: The Journal of Lifelong Learning in Psychiatry July 1, 2023 Allison A. Feduccia, Lisa Jerome, Berra Yazar-Klosinski et al. 24 citations

Unsuccessfully treated posttraumatic stress disorder (PTSD) is a serious and life-threatening disorder. Two medications, paroxetine hydrochloride and sertraline hydrochloride, are approved treatments for PTSD by the Food and Drug Administration (FDA). Analyses of pharmacotherapies for PTSD found only small to moderate effects when compared with placebo. The Multidisciplinary Association for...

Effects of Selective Serotonin Reuptake Inhibitor Use on 3,4-Methylenedioxymethamphetamine–Assisted Therapy for Posttraumatic Stress Disorder

Journal of Clinical Psychopharmacology September 1, 2022 Collin M. Price, Allison A. Feduccia, Katrina Debonis

Abstract Background Among the renewed applications of psychedelic medicines in psychiatry, 3,4-methylenedioxymethamphetamine (MDMA)–assisted therapy for posttraumatic stress disorder (PTSD) has demonstrated the most promise in early small-scale studies. Recent exploratory analyses from prior clinical trials of MDMA-assisted therapy for PTSD have suggested that recent use of selective serotonin...

Sleep Quality Improvements After MDMA-Assisted Psychotherapy for the Treatment of Posttraumatic Stress Disorder.

Journal of Traumatic Stress August 1, 2021 Linnae Ponté, Lisa Jerome, Scott Hamilton et al. 42 citations Expression of concern

Sleep disturbances (SDs) are among the most distressing and commonly reported symptoms in posttraumatic stress disorder (PTSD). Despite increased attention on sleep in clinical PTSD research, SDs remain difficult to treat. In Phase 2 trials, 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy has been shown to greatly improve PTSD symptoms. We hypothesized that MDMA-assisted...

DOI: 10.1002/jts.22696 (opens in new tab) Full text (opens in new tab) Psychedelic therapy PTSD Treatment Trauma treatment Mental health recovery +16

Scaling Up: Multisite Open-Label Clinical Trials of MDMA-Assisted Therapy for Severe Posttraumatic Stress Disorder

Journal of Humanistic Psychology June 23, 2021 Julie B. Wang, Jessica Lin, Leah Bedrosian et al. 22 citations

Background: Posttraumatic stress disorder (PTSD) is a debilitating mental health condition associated with serious adverse health outcomes and functional impairment. Previous MDMA–assisted therapy (MDMA-AT) studies have shown promising results in single site studies. Two open-label studies tested this modality in multisite clinical trials to assess the feasibility of scaling this manualized...

DOI: 10.1177/00221678211023663 (opens in new tab) Psychedelic therapy PTSD Treatment Trauma therapy Mental health treatment +15

MDMA-facilitated cognitive-behavioural conjoint therapy for posttraumatic stress disorder: an uncontrolled trial.

European Journal of Psychotraumatology December 7, 2020 Candice M Monson, Anne C Wagner, Ann T Mithoefer et al. 90 citations

Cognitive-behavioural conjoint therapy (CBCT) for PTSD has been shown to improve PTSD, relationship adjustment, and the health and well-being of partners. MDMA (3,4-methylenedioxymethamphetamine) has been used to facilitate an individual therapy for PTSD. This study was an initial test of the safety, tolerability, and efficacy of MDMA-facilitated CBCT. Six couples with varying levels of...

DOI: 10.1080/20008198.2020.1840123 (opens in new tab) Full text (opens in new tab) Cognitive-behavioural Conjoint Couple MDMA-Assisted Therapy MDMA +14

MDMA-assisted psychotherapy for treatment of anxiety and other psychological distress related to life-threatening illnesses: a randomized pilot study

Scientific Reports November 24, 2020 Julane Andries, Lisa Jerome, Evan Sola et al. 170 citations

Abstract The success of modern medicine creates a growing population of those suffering from life-threatening illnesses (LTI) who often experience anxiety, depression, and existential distress. We present a novel approach; investigating MDMA-assisted psychotherapy for the treatment of anxiety in people with an LTI. Participants with anxiety from an LTI were randomized in a double-blind study to...

Discontinuation of medications classified as reuptake inhibitors affects treatment response of MDMA-assisted psychotherapy.

Psychopharmacology November 21, 2020 Allison A. Feduccia, Lisa Jerome, Michael C Mithoefer et al. 39 citations Retracted

Abstract Rationale MDMA-assisted psychotherapy is under investigation as a novel treatment for posttraumatic stress disorder (PTSD). The primary mechanism of action of MDMA involves the same reuptake transporters targeted by antidepressant medications commonly prescribed for PTSD. Objectives Data were pooled from four phase 2 trials of MDMA-assisted psychotherapy. To explore the effect of...

Long-term follow-up outcomes of MDMA-assisted psychotherapy for treatment of PTSD: a longitudinal pooled analysis of six phase 2 trials.

Psychopharmacology August 1, 2020 Lisa Jerome, Allison A. Feduccia, Julie B. Wang et al. 163 citations Retracted

Posttraumatic stress disorder (PTSD) is a chronic condition that has wide-ranging negative effects on an individual's health and interpersonal relationships. Treatments with long-term benefits are needed to promote the safety and well-being of those suffering from PTSD. To examine long-term change in PTSD symptoms and additional benefits/harms after 3,4-methylenedioxymethamphetamine...

Integrating psychotherapy and psychopharmacology: psychedelic-assisted psychotherapy and other combined treatments

Expert Review of Clinical Pharmacology June 1, 2020 Kyle T. Greenway, Nicolas Garel, Lisa Jerome et al. 87 citations

INTRODUCTION: Combinations of psychotherapy with antidepressants are gold-standard psychiatric treatments. They operate through complex and interactional mechanisms, not unlike the reemergent paradigm of psychedelic-assisted psychotherapy, which promising research suggests may also be highly effective in even challenging populations. AREAS COVERED: We review the therapeutic mechanisms behind...

Posttraumatic Growth After MDMA‐Assisted Psychotherapy for Posttraumatic Stress Disorder

Journal of Traumatic Stress February 19, 2020 Ingmar Gorman, Alexander Belser, Lisa Jerome et al. 43 citations Expression of concern

Abstract 3,4‐Methylenedioxymethamphetamine (MDMA)–assisted psychotherapy for posttraumatic stress disorder (PTSD) has been shown to significantly reduce clinical symptomatology, but posttraumatic growth (PTG), which consists of positive changes in self‐perception, interpersonal relationships, or philosophy of life, has not been studied with this treatment. Participant data ( n = 60) were pooled...

DOI: 10.1002/jts.22479 (opens in new tab) MDMA Placebo Posttraumatic stress Posttraumatic growth +3

Breakthrough for Trauma Treatment: Safety and Efficacy of MDMA-Assisted Psychotherapy Compared to Paroxetine and Sertraline

Frontiers in Psychiatry September 12, 2019 Allison A. Feduccia, Lisa Jerome, Berra Yazar-Klosinski et al. 172 citations

Unsuccessfully treated posttraumatic stress disorder (PTSD) is a serious and life-threatening disorder. Two medications, paroxetine hydrochloride and sertraline hydrochloride, are approved treatments for PTSD by the Food and Drug Administration (FDA). Analyses of pharmacotherapies for PTSD found only small to moderate effects when compared with placebo. The Multidisciplinary Association for...

DOI: 10.3389/fpsyt.2019.00650 (opens in new tab) MDMA Paroxetine Sertraline Psychotherapist

MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials.

Psychopharmacology September 1, 2019 Michael C Mithoefer, Allison A. Feduccia, Lisa Jerome et al. 364 citations Retracted

Posttraumatic stress disorder is a prevalent mental health condition with substantial impact on daily functioning that lacks sufficient treatment options. Here we evaluate six phase 2 trials in a pooled analysis to determine the study design for phase 3 trials of MDMA-assisted psychotherapy for PTSD. Six randomized, double-blind, controlled clinical trials at five study sites were conducted...

DOI: 10.1007/s00213-019-05249-5 (opens in new tab) Full text (opens in new tab) MDMA-Assisted Psychotherapy Posttraumatic stress disorder MDMA Alongside Therapy Active MDMA +7

3,4-Methylenedioxymethamphetamine-assisted psychotherapy for treatment of chronic posttraumatic stress disorder: A randomized phase 2 controlled trial.

Journal of Psychopharmacology December 1, 2018 Marcela Ot'Alora G, Jim Grigsby, Bruce Poulter et al. 232 citations

Posttraumatic stress disorder often does not resolve after conventional psychotherapies or pharmacotherapies. Pilot studies have reported that 3,4-methylenedioxymethamphetamine (MDMA) combined with psychotherapy reduces posttraumatic stress disorder symptoms. This pilot dose response trial assessed efficacy and safety of MDMA-assisted psychotherapy across multiple therapy teams. Twenty-eight...

DOI: 10.1177/0269881118806297 (opens in new tab) Full text (opens in new tab) Serotonin 3,4-Methylenedioxymethamphetamine MDMA Oxytocin Posttraumatic stress disorder +16

Reduction in social anxiety after MDMA-assisted psychotherapy with autistic adults: a randomized, double-blind, placebo-controlled pilot study.

Psychopharmacology November 1, 2018 Alicia Danforth, Charles S. Grob, Christopher M Struble et al. 284 citations

Standard therapeutic approaches to reduce social anxiety in autistic adults have limited effectiveness. Since 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy shows promise as a treatment for other anxiety disorders, a blinded, placebo-controlled pilot study was conducted. To explore feasibility and safety of MDMA-assisted psychotherapy for reduction of social fear and avoidance...

DOI: 10.1007/s00213-018-5010-9 (opens in new tab) Full text (opens in new tab) 3,4-methylenedioxymethamphetamine Asperger’s Social anxiety MDMA-Assisted Psychotherapy: 3 +2

MDMA-assisted psychotherapy for PTSD: Are memory reconsolidation and fear extinction underlying mechanisms?

Progress in Neuro-Psychopharmacology and Biological Psychiatry June 8, 2018 Allison A. Feduccia, Michael C Mithoefer 213 citations

MDMA-assisted psychotherapy for treatment of PTSD has recently progressed to Phase 3 clinical trials and received Breakthrough Therapy designation by the FDA. MDMA used as an adjunct during psychotherapy sessions has demonstrated effectiveness and acceptable safety in reducing PTSD symptoms in Phase 2 trials, with durable remission of PTSD diagnosis in 68% of participants. The underlying...

DOI: 10.1016/j.pnpbp.2018.03.003 (opens in new tab) Full text (opens in new tab) Amygdala Fear extinction Hippocampus MDMA-Assisted Psychotherapy +2

3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for post-traumatic stress disorder in military veterans, firefighters, and police officers: a randomised, double-blind, dose-response, phase 2 clinical trial.

The Lancet Psychiatry May 1, 2018 Michael C Mithoefer, Ann T Mithoefer, Allison A. Feduccia et al. 443 citations

Background: Post-traumatic stress disorder (PTSD) is prevalent in military personnel and first responders, many of whom do not respond to currently available treatments. This study aimed to assess the efficacy and safety of 3,4-methylenedioxymethamphetamine (MDMA)-assisted psychotherapy for treating chronic PTSD in this population. Methods: We did a randomised, double-blind, dose-response,...

DOI: 10.1016/s2215-0366(18)30135-4 (opens in new tab) This condition PTSD Symptoms Profound trauma Significant relief +10

Progress and promise for the MDMA drug development program.

Psychopharmacology November 20, 2017 Allison A. Feduccia, Julie Holland, Michael C Mithoefer 79 citations

Pharmacotherapy is often used to target symptoms of posttraumatic stress disorder (PTSD), but does not provide definitive treatment, and side effects of daily medication are often problematic. Trauma-focused psychotherapies are more likely than drug treatment to achieve PTSD remission, but have high dropout rates and ineffective for a large percentage of patients. Therefore, research into drugs...

DOI: 10.1007/s00213-017-4779-2 (opens in new tab) Psychedelic therapy MDMA Therapy MDMA-Assisted Psychotherapy MDMA Treatment +21

Heat increases MDMA-enhanced NAcc 5-HT and body temperature, but not MDMA self-administration.

European Neuropsychopharmacology December 2010 Allison A. Feduccia, Nundhun Kongovi, Christine L. Duvauchelle

There is a concern that hot environments enhance adverse effects of 3,4-methylenedioxymethamphetamine (MDMA or "Ecstasy"). In this study, long-term (4-weeks) daily MDMA self-administration sessions and an MDMA Challenge test were conducted with rats under normal and high thermal conditions (23° or 32°C). During MDMA self-administration sessions, activity and body temperature were increased by...

Auditory stimuli enhance MDMA-conditioned reward and MDMA-induced nucleus accumbens dopamine, serotonin and locomotor responses.

Brain Research Bulletin October 22, 2008 Allison A. Feduccia, Christine L. Duvauchelle

MDMA (3,4-methylenedioxymethamphetamine), also known as ecstasy, is a popular drug often taken in environments rich in audio and visual stimulation, such as clubs and dance parties. The present experiments were conducted to test the notion that auditory stimulation influences the rewarding effects of MDMA. In Experiment 1, a conditioned place preference (CPP) procedure was conducted in which...